These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Pregnancy and breastfeeding in women with multiple sclerosis]. Witt L; Thiel S; Hellwig K Nervenarzt; 2024 Apr; 95(4):329-334. PubMed ID: 38393359 [TBL] [Abstract][Full Text] [Related]
23. Does pregnancy affect women with multiple sclerosis? A prospective study in Western China. Lai W; Kinoshita M; Peng A; Li W; Qiu X; Zhu X; He S; Zhang L; Chen L J Neuroimmunol; 2018 Aug; 321():24-28. PubMed ID: 29957384 [TBL] [Abstract][Full Text] [Related]
24. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse. Cohen BA; Coyle PK; Leist T; Oleen-Burkey MA; Schwartz M; Zwibel H Mult Scler Relat Disord; 2015 Jan; 4(1):75-82. PubMed ID: 25787057 [TBL] [Abstract][Full Text] [Related]
25. Pregnancy in multiple sclerosis. Hellwig K Eur Neurol; 2014; 72 Suppl 1():39-42. PubMed ID: 25278125 [TBL] [Abstract][Full Text] [Related]
26. Oral contraceptives and MS disease activity in a contemporary real-world cohort. Bove R; Rankin K; Chua AS; Saraceno T; Sattarnezhad N; Greeke E; Stuart F; LaRussa A; Glanz BI; Chitnis T Mult Scler; 2018 Feb; 24(2):227-230. PubMed ID: 28155573 [TBL] [Abstract][Full Text] [Related]
27. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Hellwig K; Brune N; Haghikia A; Müller T; Schimrigk S; Schwödiauer V; Gold R Acta Neurol Scand; 2008 Jul; 118(1):24-8. PubMed ID: 18205883 [TBL] [Abstract][Full Text] [Related]
28. Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. Ghezzi A; Annovazzi P; Portaccio E; Cesari E; Amato MP Expert Rev Clin Immunol; 2013 Jul; 9(7):683-91; quiz 692. PubMed ID: 23899239 [TBL] [Abstract][Full Text] [Related]
29. Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients. Johnson BH; Bonafede MM; Watson C CNS Drugs; 2015 Jun; 29(6):503-10. PubMed ID: 26113055 [TBL] [Abstract][Full Text] [Related]
30. [An effect of disease-modifying drugs on the development of children born to mothers with multiple sclerosis]. Kasatkin DS; Spirin NN; Vinogradova TV; Shytova AS Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2. Vyp. 2):85-91. PubMed ID: 28617366 [TBL] [Abstract][Full Text] [Related]
31. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Achiron A; Barak Y; Gail M; Mandel M; Pee D; Ayyagari R; Rotstein Z Breast Cancer Res Treat; 2005 Feb; 89(3):265-70. PubMed ID: 15754125 [TBL] [Abstract][Full Text] [Related]
32. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Kalincik T; Jokubaitis V; Izquierdo G; Duquette P; Girard M; Grammond P; Lugaresi A; Oreja-Guevara C; Bergamaschi R; Hupperts R; Grand'Maison F; Pucci E; Van Pesch V; Boz C; Iuliano G; Fernandez-Bolanos R; Flechter S; Spitaleri D; Cristiano E; Verheul F; Lechner-Scott J; Amato MP; Cabrera-Gomez JA; Saladino ML; Slee M; Moore F; Gray O; Paine M; Barnett M; Havrdova E; Horakova D; Spelman T; Trojano M; Butzkueven H; Mult Scler; 2015 Aug; 21(9):1159-71. PubMed ID: 25480857 [TBL] [Abstract][Full Text] [Related]
33. Effects of multiple sclerosis and medications on menopausal age. Türk Börü Ü; Köseoğlu Toksoy C; Bölük C; Bilgiç A; Taşdemir M J Int Med Res; 2018 Mar; 46(3):1249-1253. PubMed ID: 29332426 [TBL] [Abstract][Full Text] [Related]
34. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. Giannini M; Portaccio E; Ghezzi A; Hakiki B; Pastò L; Razzolini L; Piscolla E; De Giglio L; Pozzilli C; Paolicelli D; Trojano M; Marrosu MG; Patti F; La Mantia L; Mancardi G; Solaro C; Totaro R; Tola MR; De Luca G; Lugaresi A; Moiola L; Martinelli V; Comi G; Amato MP BMC Neurol; 2012 Oct; 12():124. PubMed ID: 23088447 [TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs. Tsareva E; Kulakova O; Boyko A; Favorova O Pharmacogenet Genomics; 2016 Mar; 26(3):103-15. PubMed ID: 26678572 [TBL] [Abstract][Full Text] [Related]
36. Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies. Izquierdo G; García-Agua Soler N; Rus M; García-Ruiz AJ Brain Behav; 2015 Jun; 5(6):e00337. PubMed ID: 26085963 [TBL] [Abstract][Full Text] [Related]
37. Epidemiological characteristics of pregnancy, delivery, and birth outcome in women with multiple sclerosis in Argentina (EMEMAR study). Fernández Liguori N; Klajn D; Acion L; Cáceres F; Calle A; Carrá A; Cristiano E; Deri N; Garcea O; Jaureguiberry A; Onaha P; Patrucco L; Riccio P; Rotta Escalante R; Saladino Ml; Sinay V; Tarulla A; Villa A Mult Scler; 2009 May; 15(5):555-62. PubMed ID: 19299437 [TBL] [Abstract][Full Text] [Related]
38. Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. Spelman T; Mekhael L; Burke T; Butzkueven H; Hodgkinson S; Havrdova E; Horakova D; Duquette P; Izquierdo G; Grand'Maison F; Grammond P; Barnett M; Lechner-Scott J; Alroughani R; Trojano M; Lugaresi A; Granella F; Pucci E; Vucic S; Eur J Neurol; 2016 Apr; 23(4):729-36. PubMed ID: 26782663 [TBL] [Abstract][Full Text] [Related]